BPTH (Bio-Path Holdings) Total Liabilities: $9.16 Mil (As of Mar. 2026)


What is Bio-Path Holdings Total Liabilities?

Bio-Path Holdings BPTH -19.63% Total Liabilities is $9.16 Mil as of Mar. 2026. The stock has 1 warning sign investors should review.

Bio-Path Holdings's Total Liabilities for the quarter that ended in Mar. 2026 was $9.16 Mil.

Bio-Path Holdings's quarterly Total Liabilities increased from Jun. 2025 ($7.90 Mil) to Sep. 2025 ($8.70 Mil) and increased from Sep. 2025 ($8.70 Mil) to Mar. 2026 ($9.16 Mil).

Bio-Path Holdings's annual Total Liabilities increased from Dec. 2022 ($1.80 Mil) to Dec. 2023 ($2.78 Mil) and increased from Dec. 2023 ($2.78 Mil) to Dec. 2024 ($3.73 Mil).

Bio-Path Holdings Total Liabilities Historical Data

* Premium members only.

The historical data trend for Bio-Path Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Path Holdings Total Liabilities Chart

Bio-Path Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.41 1.11 1.80 2.78 3.73

Bio-Path Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.73 4.78 7.90 8.70 9.16

Bio-Path Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Bio-Path Holdings's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.295+(0+0.434
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=3.73

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=3.883-0.154
=3.73

Bio-Path Holdings's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=9.151+(0+0.012
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=9.16

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=0.677--8.486
=9.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $9.16 Mil mean?
Bio-Path Holdings (BPTH) has a Total Liabilities of $9.16 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Bio-Path Holdings and its competitors.
Is Bio-Path Holdings' Total Liabilities too high?
Bio-Path Holdings' current Total Liabilities is $9.16 Mil.
How does Bio-Path Holdings' Total Liabilities compare to ADAPY and ZVSA?
Bio-Path Holdings' Total Liabilities of $9.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Bio-Path Holdings and its competitors. Bio-Path Holdings's current Total Liabilities is $9.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Path Holdings stock overvalued right now?
Bio-Path Holdings (BPTH) has a current Total Liabilities of $9.16 Mil. The current Total Liabilities is $9.16 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Bio-Path Holdings (BPTH), the current Total Liabilities is $9.16 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Path Holdings Business Description

Address No. 2407, 625 Stanwix Street, Pittsburgh, PA, USA, 15222
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.